Home » Newsletters » BioWorld Science

BioWorld Science

July 30, 2009

View Archived Issues

Phase II data show that citalopram has similar effects to antipsychotics in AD patients

Safety and efficacy of memantine in Alzheimer's disease reported at ICAD

Lymphotoxin-alpha targeting antibody S5H3 inhibits autoimmune disease in mice

Labeled polypeptides for the diagnosis of fibrosis described by INSERM

Roche claims non-nucleoside reverse transcriptase inhibitors for the treatment of HIV and AIDS

Tubulin polymerization inhibitors for cancer therapy disclosed by Universita degli studi di Milano

Glenmark Pharmaceuticals presents VR1 receptor antagonists for the treatment of pain

Bayer Schering Pharma claims HNE inhibitors for pulmonary hypertension, COPD, etc.

Ariad presents preliminary data from two ongoing ridaforolimus trials in cancer

CSL begins shipment of influenza virus vaccine for 2009-2010 flu season

FDA accepts CyDex's IND for phase IIa study of CDX-353 in multiple myeloma

RXi acquires exclusive worldwide license to Advirna's RNAi delivery technology

BrainCells reports results from a clinical proof-of-concept study of BCI-952 in MDD

FDA issues EUA for Focus Diagnostics' influenza H1N1 virus test

Phytopharm and CHDI sign agreement to evaluate Cogane in preclinical model of HD

Asenapine meets primary endpoint in long-term extension study in schizophrenia

Dirucotide does not meet primary endpoint in phase III MAESTRO-01 trial in MS

Amgen to collaborate with GSK to commercialize denosumab in Europe

Biofrontera reports efficacy data for BF-derm1 in severe chronic urticaria

Acceleron and Celgene begin phase II ACE-011 study for chemotherapy-induced anemia

Sanofi launches Multaq in the U.S. for atrial fibrillation or atrial flutter

Novartis launches Clozaril for treatment-resistant schizophrenia in Japan

Takeda submits NDA in Japan for fixed-dose combination of pioglitazone and glimepiride

ELND-005 displays safety and favorable pharmacokinetics in humans and rodents

CG3R6TAT nanoparticles cross blood-brain barrier, show enhanced antimicrobial activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...